Screening for diabetic nephropathy: take your blinkers off

@article{Eid2018ScreeningFD,
  title={Screening for diabetic nephropathy: take your blinkers off},
  author={Ahmed Mohamed Eid and Shafiq Yusuff and M F Kong},
  journal={British Journal of Diabetes},
  year={2018}
}
Proteinuria is one of several markers of kidney damage in diabetes. The excretion of specific types of protein, such as albumin or low molecular weight globulins, depends on the type of kidney disease that is present.1 One of the earliest changes in diabetes is an increase in glomerular filtration rate (GFR), or hyperfiltration, which is observed in patients with type 1 as well as many with type 2 diabetes and is accompanied by an increase in renal size.2 The next observable change is the… 
1 Citation

Tables from this paper

Impact of chrysin on the molecular mechanisms underlying diabetic complications

The findings indicate that chrysin has protective effects against diabetes outcomes by modulating oxidative stress, inflammation, and apoptosis in animal models, however, more clinical trial study should be done to clear the protective effects of chrys in diabetic patients.

Spectrum of renal diseases associated with extreme forms of insulin resistance.

In patients with syndromic forms of insulin resistance and type 2 diabetes, renal biopsy has an important role in defining the pathology that leads to proteinuric nephropathy and in formulating a therapeutic approach.

Rate and Determinants of Association Between Advanced Retinopathy and Chronic Kidney Disease in Patients With Type 2 Diabetes

OBJECTIVE To evaluate the rate and determinants of concordance between advanced diabetic retinopathy (DR) and chronic kidney disease (CKD), as assessed by both albuminuria and estimated glomerular

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

  • Kdoqi Disclaimer
  • Medicine
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2002
Initiation of treatment for cardiovascular risk factors at earlier stages of chronic kidney disease should be effective in reducing cardiovascular disease events both before and after the onset of kidney failure.

Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume.

It is concluded that long term lithium treatment increases circulating biologically active PTH and causes parathyroid enlargement, which might lead to adenoma formation in certain susceptible individuals and whether a PTH-induced increase in skeletal remodelling occurs that might hasten the appearance of osteopenia.

Measurement of microalbuminuria--what the nephrologist should know.

  • J. Redón
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2006